Center-Authored Papers

Filters: Author is Szymonifka, Jackie  [Clear All Filters]
2013
Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y et al..  2013.  Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker.. Journal of the National Cancer Institute. 105(14):1036-1042. Abstract
Papanikolaou X, Szymonifka J, Rosenthal A, Heuck CJ, Mitchell A, Johann D, Keller J, Waheed S, Usmani SZ, van Rhee F et al..  2013.  Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.. Haematologica. 98(7):1147-53. Abstract
2011
Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B.  2011.  International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.. Cancer. 117(5):1001-9. Abstract
2010
Nair B, van Rhee F, Shaughnessy JD, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B.  2010.  Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.. Blood. 115(21):4168-73. Abstract
Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BGM, Harousseau J-L.  2010.  Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(7):1209-14. Abstract
Barlogie B, Anaissie E, van Rhee F, Shaughnessy JD, Szymonifka J, Hoering A, Petty N, Crowley J.  2010.  Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3023-7. Abstract
van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy JD, Hoering A, Crowley J et al..  2010.  Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.. Blood. 116(8):1220-7. Abstract
2009
Dhodapkar MV, Hoering A, Gertz MA, Rivkin S, Szymonifka J, Crowley J, Barlogie B.  2009.  Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.. Blood. 113(4):793-6. Abstract
Hoering A, Crowley J, Shaughnessy JD, Hollmig K, Alsayed Y, Szymonifka J, Waheed S, Nair B, van Rhee F, Anaissie E et al..  2009.  Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.. Blood. 114(7):1299-305. Abstract